Balchem (BCPC) Q3 2026 earnings summary

Executive summary

• Record Q3 sales of $290.658M, GAAP net earnings of $46.728M and adjusted EBITDA of $80.3M; all three segments grew sales and operating earnings.

• Adjusted EBITDA increased YoY for the 29th consecutive quarter, reflecting portfolio strength and resilience across market conditions.

Financial highlights

• Q3 net sales rose 8.6% to $290.658M; operating earnings increased 14.4% to $62.437M, net earnings rose 16.0% to $46.728M and diluted EPS was $1.46.

• Adjusted EBITDA grew 12.4% to $80.3M; adjusted net earnings rose 14.5% to $50.4M and adjusted diluted EPS increased 16.3% to $1.57.

• Gross profit increased 10.7% to $105.714M; gross margin expanded 70 bps to 36.4%, with growth, favorable mix and manufacturing efficiencies partly offset by higher input costs.

• 9M sales rose 9.3% to $845.364M; net earnings increased 13.8% to $131.628M, adjusted EBITDA grew 12.4% to $232.5M and adjusted net earnings rose 12.6% to $141.4M.

• 9M diluted EPS was $4.09 and adjusted diluted EPS was $4.40, up from $3.54 and $3.84, respectively.

Outlook and guidance

• Q4 is normally sequentially lower than Q3 due to seasonality; management expected healthy YoY growth to continue.

• Human Nutrition & Health outlook remained positive; Animal Nutrition & Health management cited potential for further technology penetration and long-term growth.

• Growth priorities include innovation, product launches, market penetration, geographic expansion, adjacent capabilities and targeted M&A.